Ms artificially induced in humans by mistake

A forum to discuss research on the origins of MS and its development.
Post Reply
User avatar
frodo
Family Elder
Posts: 1749
Joined: Wed Dec 02, 2009 3:00 pm
Contact:

Ms artificially induced in humans by mistake

Post by frodo »

Sometimes some MS patients get a kind of artificially induced MS while they are treated for other conditions. There are several reports about it since 2001, and currently these diseases cannot be distinguished from real MS.

These "models" probably can be induced in animals and they would be closer to real MS than EAE in mice. I don't understand why researchers are still using that EAE thing.

The following report speaks about a patient who got a primary progressive course, but RRMS and SPMS have also been reported. This speaks about a drug named adalimumab, but also with other drugs has been reported (pembrolizumab and infliximab)

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

Abstract

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing–remitting MS (RRMS).

We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after treatment initiation, he developed slowly progressing neurological deficits including gait impairment, paraesthesia of the lower limbs, strangury and visual impairment, which led to the discontinuation of adalimumab therapy.

Magnetic resonance imaging of the brain and the spinal cord revealed multiple inflammatory lesions and cerebrospinal fluid examination showed slight pleocytosis and positive oligoclonal bands. Thus, PPMS was diagnosed according to the 2017 revision of the McDonald criteria.

As PPMS often causes only subtle symptoms in the beginning and early treatment discontinuation of anti-TNF-α therapy seems essential to improve the patient’s outcome, we think that it is important to increase the awareness of slowly progressing neurological deficits as a potential adverse event of anti-TNF-α therapy among all clinicians involved in the initiation and monitoring of these drugs. In addition, the occurrence of both RRMS and progressive MS upon anti-TNF-α therapy might suggest a shared TNF-α-mediated pathophysiological mechanism in the evolution of all MS subtypes.
Last edited by frodo on Fri May 08, 2020 1:23 am, edited 2 times in total.
User avatar
frodo
Family Elder
Posts: 1749
Joined: Wed Dec 02, 2009 3:00 pm
Contact:

It seems that they are working with TNF in mice

Post by frodo »

Well. Not the same but I have found a paper in which they describe the action of TNF in mice, similar to the previous auto-antibody.

TNFR2 limits proinflammatory astrocyte functions during EAE induced by pathogenic DR2b-restricted T cells

https://insight.jci.org/articles/view/1 ... ign=buffer

Image
User avatar
frodo
Family Elder
Posts: 1749
Joined: Wed Dec 02, 2009 3:00 pm
Contact:

New case

Post by frodo »

New Developing Multiple Sclerosis in A Patient Using Tofacitinib Due To Alopesia Areata

https://onlinelibrary.wiley.com/doi/abs ... /dth.15477
Post Reply

Return to “MS Etiology and Pathogenesis”